Published:
Friday, May 24, 2013 10:17 AM PDT
One of the biopharmaceutical companies that has been lagging the stellar performance of its peers is Exelixis (NADSAQ: EXEL), developer of the compound cabozantinib. Cabo, which was FDA approved last year for the treatment of medullary thyroid cancer (MTC), is now being marketed under the trade name COMETRIQ. In the company’s reported Q1 2013 earnings release on May 7th, the company was able to present some early results for the drug’s performance on the open market although it’s difficult to accurately interpret a drug’s intrinsic monetary potential with only a few weeks of sales data and estimates on the drug’s penetration into a market.
Published:
Friday, May 24, 2013 8:41 AM PDT
With one small move, Plug Power Inc. (NASDAQ:PLUG) just turned itself into a compelling trade.
Published:
Friday, May 24, 2013 7:21 AM PDT
If it's not, LeapFrog Enterprises, Inc. (NYSE:LF) should certainly be on the radars of Mattel, Inc. (NASDAQ:MAT) and Hasbro, Inc. (NASDAQ:HAS).
Published:
Friday, May 24, 2013 4:22 AM PDT
The latest good news coming out of the Williston Basin’s Bakken and Three Forks formations plus players there like Samson Oil & Gas Limited (SSN), Nuverra Environmental Solutions Inc (NES) and Norstra Energy, Inc (NORX).
» Read More
Published:
Thursday, May 23, 2013 11:24 PM PDT
Move over Sony Corporation (SNE) or Canon Inc. (CAJ): A quick look a Japanese small cap or mid cap stocks Internet Initiative Japan Inc. (IIJI), Advantest Corp (ATE) and Konami Corp (KNM) verses small cap Japan ETFs.
» Read More
Published:
Thursday, May 23, 2013 12:50 PM PDT
VIVUS, Inc. (NASDAQ:VVUS) has been spinning its wheels for quite some time, but today's breakout is apt to create the very melt-up the market was waiting to see.
Published:
Thursday, May 23, 2013 11:25 AM PDT
Cancer Genetics (OTCQB: CGIX), a developer of DNA-based cancer diagnostics, is one of the most compelling opportunities we've seen in 2013.
Published:
Thursday, May 23, 2013 11:19 AM PDT
Paul Burgess, CEO of Lattice Inc. (OTCBB: LTTC), a provider of secure cloud-based communications technology for correctional facilities, was recently interviewed by The Wall Street Analyst.
Published:
Thursday, May 23, 2013 11:08 AM PDT
Amarin, on the whole, seems to have fallen out of favor in the biotech investment community. This may change as we head closer to December 20th (or after an unexpected announcement), but without a tangible piece of news that can positively affect Vascepa’s sales figures or its financial valuation don’t expect much more than a continuation of what we’ve seen this year.
Published:
Thursday, May 23, 2013 7:54 AM PDT
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is rolling again. Take it at face value.
